Blemaren effervescent tablets N80

Release form and packaging

Effervescent tablets white, round, flat, faceted, with a lemon scent.

20 pcs.

- plastic tubes (4) complete with a control calendar and indicator paper - cardboard packs.

pharmachologic effect

A drug for the treatment of nephrolithiasis.

Blemaren dissolves and prevents the formation of uric acid stones by alkalizing urine to pH values ​​of 6.6–6.8 (at a pH of urine in the range of 6.6–6.8, the dissolution of uric acid salts significantly increases).

In addition, it reduces the excretion of calcium, improves the solubility of calcium oxalate in urine, inhibits the formation of crystals and therefore prevents the formation of calcium oxalate stones.

Indications

Prevention of formation and dissolution of uric acid and calcium oxalate stones.

Dissolution of mixed uric acid-oxalate stones (with oxalate content < 25%).

Alkalinization of urine in persons receiving cytostatics or drugs that increase the excretion of uric acid.

Symptomatic treatment of skin porphyria.

Contraindications

Acute and chronic renal failure.

Metabolic alkalosis.

Urinary tract infections caused by microorganisms that break down urea.

urine pH is above 7.

The need to comply with a strict salt-free diet (for example, in severe forms of arterial hypertension).

Hypersensitivity to drug components.

Application during pregnancy and lactation

There are no data on the safety of using Blemaren during pregnancy and lactation, and therefore it is not recommended to use the drug during these periods.

special instructions

The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium, which should be taken into account when prescribing the drug to patients on a diet with limited salt intake.

The drug can be used in chronic renal failure, not accompanied by a retention of potassium ions.

It is possible to prescribe the drug to patients with diabetes mellitus.

When dissolving uric acid stones, the daily dose should not be exceeded, since with an increase in pH above 7.0, phosphates precipitate on uric acid crystals, which prevents their further dissolution.

During treatment, you should limit the intake of foods rich in proteins and purine bases, and ensure adequate fluid intake (not < 1.5-2 liters).

Structure

1 tablet contains:

Active ingredients: citric acid - 1.197 g

potassium bicarbonate - 967.5 mg

sodium citrate - 835.5 mg.

Excipients: lactose monohydrate - 115 mg, mannitol - 105 mg, adipic acid - 35 mg, macrogol 6000 - 100 mg, sodium saccharinate - 10 mg, lemon flavor - 35 mg.

Method of administration and dosage

Effervescent tablets are dissolved in 200 ml of liquid (tea, fruit juices or alkaline mineral water) before ingestion.

The daily dose is 2-6 tablets.

The daily dose is evenly distributed throughout the day and taken after meals.

The dose is considered correctly selected if the pH of urine during the day is within 6.2 -7 - to dissolve uric acid stones

7.5 - 8.5 - to dissolve cystine stones

7.2-7.5 - for the treatment of porphyria

at least 7.0 - during treatment with cytostatics.

If the urine pH is below the specified value, the dose should be increased, if it is higher, it should be decreased.

The duration of treatment is 4-6 months.

Efficiency control (determination of urine pH) is carried out 3 times / day, before taking each single dose using indicator paper.

The obtained color on paper is compared within 2 minutes with a scale and the obtained value is entered into a control calendar.

In the presence of cystine stones and the treatment of porphyria, a special indicator paper with a pH value of 7.2 to 9.7 should be used to monitor the effectiveness.

Side effects

Possibly: allergic reactions, edema (sodium retention), metabolic a

Name ENG

BLEMAREN

Clinical and pharmacological group

The drug used for urolithiasis

ATX code

Drugs for the treatment of nephrourolithiasis

Dosage

967.5mg + 1.197g + 835.5mg

Structure

1 tablet contains: Active ingredients: citric acid - 1.197 g

potassium bicarbonate - 967.5 mg

sodium citrate - 835.5 mg.

Excipients: lactose monohydrate - 115 mg, mannitol - 105 mg, adipic acid - 35 mg, macrogol 6000 - 100 mg, sodium saccharinate - 10 mg, lemon flavor - 35 mg.

Indications

Prevention of the formation and dissolution of uric acid and calcium oxalate stones

dissolution of mixed uric acid-oxalate stones (with an oxalate content < 25%)

alkalinization of urine in persons receiving cytostatics or drugs that increase the excretion of uric acid

symptomatic treatment of skin porphyria.

Contraindications

Acute and chronic renal failure

metabolic alkalosis

urinary tract infections caused by microorganisms that break down urea

urine pH is higher than 7

the need for a strict salt-free diet (for example, in severe forms of arterial hypertension)

hypersensitivity to drug components

children under 12 years of age.

INN / Active ingredient

Sodium citrate + potassium bicarbonate + citric acid

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 4 years

Specifications

Category

Urolithiasis disease

,

Gout

Scope of the drug

Genitourinary system

Release form

Tablet

Manufacturer country

Spain

Package quantity, pcs

80

Vacation conditions

Without recipe

Brand name

ESPARMA

Components

indicator paper, check calendar

The amount of the dosage form in the primary package

20 pcs.

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Nephrolithiasis treatment

Anatomical and therapeutic characteristics

G04BC Drugs for the treatment of nephrourolithiasis

Dosage form

Effervescent tablets

Expiration date in days

1460

Package weight, g

150

Mode of application

:

Effervescent tablets are dissolved in 200 ml of liquid (tea, fruit juices or alkaline mineral water) before ingestion. The daily dose is 2-6 tablets. < br> The daily dose is evenly distributed throughout the day and taken after meals. < br> The dose is considered to be correctly selected if the pH of urine during the day is within the range of 6.2 -7 - to dissolve uric acid stones 7.5 - 8.5 - to dissolve cystine stones 7.2-7.5 - for the treatment of porphyria at least 7.0 - during treatment with cytostatics. < br> If the urine pH is lower than the specified, the dose must be increased, if higher - decrease. The duration of treatment is 4-6 months. < br> Efficiency control (determination of urine pH) is carried out 3 times / day, before taking each single dose using indicator paper.The resulting color on paper is compared within 2 minutes with a scale and the resulting value is entered into a control calendar. < br> In the presence of cystine stones and the treatment of porphyria, a special indicator paper with a pH value of 7.2 to 9.7 should be used to monitor the effectiveness.

Dosage (volume) of the substance in the preparation

:

1 tablet contains: < br> Active ingredients: citric acid - 1.197 g

potassium bicarbonate - 967.5 mg

sodium citrate - 835.5 mg.

Information on technical characteristics, delivery set, country of manufacture